VFA
SRNE

Valeo Financial Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Valeo Financial Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,000
Closed -$21K – 2240
2020
Q4 		$21K Buy
3,000
+1,000
+50% +$8.03K ﹤0.01% 1020
2020
Q3 		$22K Buy
+2,000
New +$18.3K ﹤0.01% 902

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Valeo Financial Advisors's SRNE Position: Q2 2023 in Review

Valeo Financial Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 27,473 shares — an estimated $9.89K sold.

Valeo Financial Advisors first reported a position in SRNE in Q2 2020 and held it in 12 quarters. The position peaked at $126K in Q2 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Valeo Financial Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Valeo Financial Advisors sold 27,473 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $9.89K.
  • Valeo Financial Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 12 quarters.
  • Valeo Financial Advisors's Sorrento Therapeutics, Inc. position peaked at $126K in Q2 2021.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Valeo Financial Advisors's 13F filing for Q2 2023, filed 14 Jul 2023.